Claus Steensen Sølje Appointed as WALK’s New CFO – A Financial Milestone for the Company!

ALK has announced that Claus Steensen Sølje will join their ranks as Executive Vice President and Chief Financial Officer (CFO) from June 1, 2023. He will also become a member of the Board of Management and will replace Søren Jelert, whose decision to leave ALK was announced in November 2022. This is an exciting development for the company, as Claus brings with him a wealth of experience and knowledge to the team.

Claus Steensen Sølje, a Danish citizen born in 1972, is bringing his impressive wealth of experience and knowledge to ALK, having spent over two decades in a variety of leadership positions at Novo Nordisk. Most recently, he has served as Senior Vice President, International Operations, from Zurich, overseeing finance, procurement, IT and supply chain for the company’s global operations outside of North America. Additionally, he has been Regional CFO for Novo Nordisk’s Emerging Markets and Country CFO for Novo Nordisk France.

Claus Steensen Sølje is a distinguished economist, boasting an M.Sc. from the University of Copenhagen (1999) as well as executive training from renowned business schools such as INSEAD, IMD and Harvard. Before joining Novo Nordisk in 2001, he gained invaluable experience working for PwC and Nykredit.

I am incredibly excited to join ALK: a company with an extraordinary history of 100 years dedicated to improving the lives of those living with allergies. It is an honor to be a part of ALK’s future growth and success, and I look forward to the journey ahead!

We are delighted to welcome Claus Elsig-Pedersen to ALK as Chief Financial Officer and member of the Board of Management. With his extensive background in finance and commercial acumen, gained from his roles at Novo Nordisk, Claus is the perfect fit for this important role. Anders Hedegaard, Chairman of the Board of Directors, and Carsten Hellmann, President & CEO, both agree that Claus will bring a wealth of knowledge and experience, and demonstrate strong leadership abilities that are sure to be of great value to ALK.

About ALK

ALK, a global specialty pharmaceutical company, is on a mission to change the lives of people with allergies and allergic asthma. With its innovative treatments, products, and services, ALK is providing relief to those who have long suffered from the debilitating effects of these conditions. Based in Hørsholm, Denmark, ALK’s team of dedicated professionals boasts a workforce of 2,700 and is proudly listed on Nasdaq Copenhage. ALK is committed to making a lasting impact in the lives of those living with allergies and asthma.

Leave a Comment